Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Context Therapeutics Inc.NASDAQ: CNTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $409.22K rose 39.3% year over year, behind the +61.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 25.8% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +39.3% toward the trailing-twelve-month pace of +61.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.33M USD
- Year-over-year change
- +58.1%
- 4-year CAGR
- +27.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.33M | +58.1% |
| FY2024 | 2024-12-31 | 841.87K | -21.8% |
| FY2023 | 2023-12-31 | 1.08M | +10.3% |
| FY2022 | 2022-12-31 | 976.44K | +91.1% |
| FY2021 | 2021-12-31 | 511.08K | — |
Stock-Based Compensation vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +61.5% is the highest of 10, against a peer median of -12.5%.
- Over three fiscal years its annual growth of +10.9% compares with a peer median of +0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M USD | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.69M USD | -12.5% | +2.7% | 768.9% | |
| LTM Mar 2026 | $7.45M USD | -5.5% | -9.2% | 5559.7% | |
| FY2025 | $3.73M USD | -44.6% | +54.6% | 5821.9% | |
| LTM Mar 2026 | €2.48M EUR | -152.9% | — | 8455.2% | |
| LTM Mar 2026 | $2.41M USD | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.28M USD | +4.3% | — | — | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
IMAImageneBio Inc | LTM Mar 2026 | $1.39M USD | -67.0% | +26.9% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $638K USD | — | — | — |
| Peer median (excluding CNTX) | — | -12.5% | +0.8% | 768.9% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.